Question 1

What is RITLECITINIB used for?

Accepted Answer

RITLECITINIB (brand name Litfulo) is a Other indicated for biologic immunomodulators, biologic immunomodulators, cyclosporine or other potent immunosuppressants ( 1 )..

Question 2

How does RITLECITINIB work?

Accepted Answer

RITLECITINIB works through the following mechanism: 12.1 Mechanism of Action LITFULO is a kinase inhibitor. Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated by JAK3-dependent receptors. Additionally, ritlecitinib inhibits signaling of immune receptors dependent on TEC kinase family members. The relevance of inhibition of specific JAK or TEC family enzymes to therapeutic effectiveness is not currently known..

Question 3

What are the most common side effects of RITLECITINIB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for RITLECITINIB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is RITLECITINIB the same as Litfulo?

Accepted Answer

Litfulo is a brand name for RITLECITINIB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

RITLECITINIB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations